Medicinal Chemistry Group

Mission Statement

 

The Medicinal Chemistry Group (MCG) aims to provide research solutions in a wide range of areas through the application of synthetic organic and medicinal chemistry expertise. Extensive experience in identifying critical issues and solving key problems enables the MCG to provide project advancement for its customers. Partnerships and collaborations with both academic and industry investigators are sought after and encouraged.

The MCG was established on the UM-St. Louis campus in 2010 by a group of former Pfizer senior scientists.  The incorporation of applied industry skill within the collaborative research environment of the university positions the MCG to deliver high quality strategy and execution of medicinal and synthetic chemistry services in several areas, including the design and synthesis of novel small molecules as potential therapeutic agents, general organic synthesis, and development of methods to identify potential clinical or lead candidates.  The chemists of the MCG have demonstrated success in identifying tractable leads from high-throughput screens, hit-to-lead optimization and in-silico based design.  A special emphasis exists in the area of neglected diseases, particularly those of the developing world.  The group seeks to discover and develop novel small molecule therapies in a wide range of therapeutic areas with the goal of bringing safe, effective, and affordable new medicines forward and translating basic research discoveries into clinically relevant therapies.

Our chemists have demonstrated expertise in the design, synthesis and development of drug candidates with the pre-requisite efficacy, safety, pharmaceutical, pharmacokinetic and pharmacodynamic properties.  They have extensive experience in evaluating and writing pharmaceutical based patents and at identifying and synthesizing tool or early lead compounds and utilizing structure-based drug design.  Practical medicinal chemistry experience is used to transform leads into promising pre-clinical candidates.  Skills also include synthetic route optimization, scale-up synthesis and working with other contract research organizations (CRO).